{"id":"CU23034","slug":"treatment-and-prevention-of--CU23034","source":{"id":"CU23034","dataset":"techtransfer","title":"Treatment and prevention of intestinal graft-versus-host disease following HPSC transplantation","description_":"<p>This technology is a method for enhancing intestinal barrier function for the prevention and treatment of graft-versus-host disease, which is often caused by allogeneic hematopoietic stem cell transplantation (HPSC). </p>\r\r<h2>Unmet Need: Prevention of stem cell transplantation-related complications</h2>\r\r<p>Allogeneic hematopoietic stem cell (HPSC) transplantation, a common therapy for various genetic diseases and cancers, often results in potentially fatal complications, such as graft-versus-host disease (GVHD). It is thought that GVHD arises from perturbations in the intestinal microbiota following allogeneic HPSC transplantation, leading to increased leukocyte activation characteristic of this complication. As such, a treatment that enhances intestinal resilience may prevent the onset of GVHD in transplant patients. </p>\r\r<h2>The Technology: GLP-2analogs for prevention and treatment of GVHD</h2>\r\r<p>This technology uses analogs of glucagon-like peptide 2 (GLP-2) to bolster intestinal barrier function in hematopoietic stem cell transplant recipients to protect against GVHD. Using a specified dosing schedule that promotes tissue repair, the proposed therapeutic regimen significantly reduces intestinal permeability that contributes to inflammation and GVHD onset. With few off-target effects and a low toxicity profile, this technology may be used in conjunction with existing therapeutic regimens to significantly reduce the incidence of GVHD in HPSC-transplant recipients.</p>\r\r<p>This technology has been validated in mouse models of allogeneic HPSC transplantation.</p>\r\r<h2>Applications:</h2>\r\r<ul>\r<li>Prevention and treatment of GVHD following HPSC transplantation</li>\r<li>Prevention of alloreactivity in solid organ transplants</li>\r<li>Treatment of toxicity after high-dose chemotherapy or radiation</li>\r<li>Therapies for autoimmune disorders of the gut (e.g. Crohn’s disease and ulcerative colitis)</li>\r</ul>\r\r<h2>Advantages:</h2>\r\r<ul>\r<li>Reduces risk of GVHD following HPSC transplantation</li>\r<li>Promotes intestinal tissue repair</li>\r<li>May be used simultaneously with existing treatment regimens</li>\r<li>High specificity of drug mechanism</li>\r<li>Few off-target effects and low toxicity profile</li>\r</ul>\r\r<h2>Lead Inventor:</h2>\r\r<p><a href=\"https://cancer.columbia.edu/ran-reshef-md\">Ran Reshef, M.D.</a></p>\r\r<h2>Patent Information:</h2>\r\r<p>Patent Pending (<a href=\"https://patents.google.com/patent/US20230364196A1/en?oq=18%2f223%2c327\">US20230364196</a>)</p>\r\r<h2>Related Publications:</h2>\r\r<h2>Tech Ventures Reference:</h2>\r\r<ul>\r<li><p>IR CU19098, CU23034, CU18125</p></li>\r<li><p>Licensing Contact: <a href=\"mailto:techtransfer@columbia.edu\">Jerry Kokoshka</a></p></li>\r</ul>\r","tags":["Allotransplantation","Chemotherapy","Graft-versus-host disease","Gut microbiota","Hematopoietic stem cell","Hematopoietic stem cell transplantation","Inflammation","Peptide","Radiation therapy","Ulcerative colitis","White blood cell"],"file_number":"CU23034","collections":[],"meta_description":"GLP-2 analogs strengthen intestinal barrier to prevent/treat GVHD after allogeneic stem cell transplantation.","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":3.0,\"timeliness\":4.0},\"weighted_score\":3.85,\"risks\":[\"Preclinical only with no human data; translation to CLINICAL may face safety/GLP-2 dosing concerns\",\"Potential redundancy with existing GVHD therapies; competition risk in GVHD space\",\"Regulatory pathway for gut-targeted GLP-2 requires thorough safety evaluation (oncogenic risk, gut hypertrophy)\"],\"one_sentence_take\":\"Strong novelty with gut-Barrier targeting and GLP-2; solid impact potential and timely, but readiness and scalability moderate pending human data and regulatory validation.\"}","inventors":["David Harle","Ran Reshef"],"manager":"Jerry Kokoshka","depts":["Medicine","Oncology"],"divs":["Columbia University Medical Center (CUMC)"],"date_released":"2026-04-21"},"highlight":{},"matched_queries":null,"score":0.0}